Recently stock market analysts have updated their consensus ratings on shares of Aptose Biosciences, Inc. (APTO).

Most recent broker ratings

03/30/2016 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 18 price target on the stock.

11/23/2015 – Aptose Biosciences, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 17 price target on the stock.

11/20/2015 – Aptose Biosciences, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 13 price target on the stock.

11/20/2015 – Aptose Biosciences, Inc. was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 4 price target on the stock.

05/01/2015 – Aptose Biosciences, Inc. had its “hold” rating reiterated by analysts at Zacks.

Aptose Biosciences, Inc. has a 50 day moving average of 2.68 and a 200 day moving average of 3.09. The stock’s market capitalization is 495.74M, it has a 52-week low of 1.93 and a 52-week high of 6.46.

The share price of the company (APTO) was down -4.23%, with a high of 2.66 during the day and the volume of Aptose Biosciences, Inc. shares traded was 17604.

View other investors thoughts on Aptose Biosciences, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.